Bill Detail

S. 4109

Congress: 119

Title

Stem Cell Therapeutic and Research Reauthorization Act of 2026

Summary

Stem Cell Therapeutic and Research Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. The bill also expands periodic reviews of the state of stem cell science to specifically include a review of the use of high-quality cord blood units and other emergent technologies to develop new therapies for potential inclusion in the program. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Sponsor

Sen. John Reed [D-RI]

Status

Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.

Status as of Nov 12, 2026, 7:12 PM · synced 4d ago

Introduced

2026-03-17

Data source mode: congress-gov

Bill Engagement

Lobbyists on the case

2 orgs · 6 lobbyists · 4 filings mention S. 4109 (Stem Cell Therapeutic and Research Reauthorization Act of 2026) in LDA disclosures.

These are cached disclosure mentions, not verified current representation or confirmed event attendance.

Top orgs filing
Lobbyists on this bill
+ 4 more in the full intelligence view

Limited preview · paid intelligence

Keep the intelligence current—not just this one record.

Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.

Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.

SEE A FINISHED HEALTHCARE EXAMPLE

Three days of Hill visits. Two Medicare access questions.

A separate, source-linked editorial example—not a dossier about this bill, an endorsement, or a claim of participation. The full records stay paid.

Read the finished healthcare brief →
Buy Federal Intelligence · $2,500 for 3 monthsPrefer a walkthrough first?Already a customer? Sign inGet free intelligence alerts →

After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.